LXRX
LEXICON PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.05
+0.74%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.06
- Revenue estimate
- $2.8M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.06
- EPS estimate
- -$0.05
- Revenue actual
- $692.0K
- Revenue estimate
- $4.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +39.9%
- Revenue beats (12Q)
- 5
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.05 | -$0.06 | Miss -19.45% | $692.0K |
| May 7, 2026 | -$0.04 | -$0.00 | Beat 93.50% | $21.1M |
| Mar 5, 2026 | -$0.07 | -$0.04 | Beat 42.86% | $5.5M |
| Nov 6, 2025 | -$0.07 | -$0.04 | Beat 42.86% | $14.2M |
| Aug 6, 2025 | -$0.08 | $0.01 | Beat 112.50% | $28.9M |
| Mar 6, 2025 | -$0.11 | -$0.09 | Beat 18.18% | $26.6M |
| Aug 1, 2024 | -$0.18 | -$0.17 | Beat 5.56% | $1.6M |
| May 2, 2024 | -$0.18 | -$0.20 | Miss -11.11% | $1.1M |
| Mar 11, 2024 | -$0.23 | -$0.20 | Beat 13.04% | $702.0K |
| Aug 3, 2023 | -$0.17 | -$0.22 | Miss -29.41% | $317.0K |
| May 2, 2023 | -$0.17 | -$0.17 | In line | $24.0K |
| Mar 2, 2023 | -$0.14 | -$0.16 | Miss -14.29% | $28.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026